Juno switched to ‘Hold’ until trial study resumes

Juno Therapeutics (JUNO) announced this morning that it has halted its mid-stage trial study on JCAR015, a leukemia treatment that has resulted in the death of two participants in the study group. At this time there is not enough information available to determine the extent to which this development may undermine Juno’s ability to gain FDA approval for this drug so we are switching to a ‘hold’ until we know more. If more information emerges over the weekend we will address it in this Monday’s issue of Breakthrough Tech Weekly.

Stock Talk

Hector Castano

Hector Castano

Jim,

What do you think about JUNO wait or buy?

Thanks,
Hector

Jim Pearce

Jim Pearce

As I discussed in today’s article (http://www.investingdaily.com/breakthrough-tech-profits/articles/28334/crunch-time-for-cancer-stocks/), I think this introduces a good entry point if you want to own Juno from a long term perspective.

Add New Comments

You must be logged in to post to Stock Talk OR create an account